CN112725219B - 一种青春双歧杆菌菌株及其应用 - Google Patents
一种青春双歧杆菌菌株及其应用 Download PDFInfo
- Publication number
- CN112725219B CN112725219B CN202011420948.4A CN202011420948A CN112725219B CN 112725219 B CN112725219 B CN 112725219B CN 202011420948 A CN202011420948 A CN 202011420948A CN 112725219 B CN112725219 B CN 112725219B
- Authority
- CN
- China
- Prior art keywords
- strain
- bifidobacterium adolescentis
- bifidobacterium
- cholesterol
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186018 Bifidobacterium adolescentis Species 0.000 title claims abstract description 60
- 230000005764 inhibitory process Effects 0.000 claims abstract description 10
- 210000003608 fece Anatomy 0.000 claims abstract description 5
- 238000012216 screening Methods 0.000 claims abstract description 5
- 241000186000 Bifidobacterium Species 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 9
- 239000002068 microbial inoculum Substances 0.000 claims description 8
- 244000052616 bacterial pathogen Species 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 6
- 244000005700 microbiome Species 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 40
- 235000012000 cholesterol Nutrition 0.000 abstract description 20
- 239000000243 solution Substances 0.000 abstract description 19
- 241000699670 Mus sp. Species 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 239000003833 bile salt Substances 0.000 abstract description 9
- 239000011550 stock solution Substances 0.000 abstract description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 abstract description 6
- 230000015556 catabolic process Effects 0.000 abstract description 6
- 238000006731 degradation reaction Methods 0.000 abstract description 6
- 241000588747 Klebsiella pneumoniae Species 0.000 abstract description 5
- 239000002253 acid Substances 0.000 abstract description 5
- 241001452028 Escherichia coli DH1 Species 0.000 abstract description 4
- 241000751185 Listeria monocytogenes ATCC 19115 Species 0.000 abstract description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 abstract description 4
- 241000607142 Salmonella Species 0.000 abstract description 4
- 241000344861 Staphylococcus aureus subsp. aureus NCTC 8325 Species 0.000 abstract description 4
- 239000004098 Tetracycline Substances 0.000 abstract description 4
- 229960002180 tetracycline Drugs 0.000 abstract description 4
- 229930101283 tetracycline Natural products 0.000 abstract description 4
- 235000019364 tetracycline Nutrition 0.000 abstract description 4
- 150000003522 tetracyclines Chemical class 0.000 abstract description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 abstract description 4
- 239000003963 antioxidant agent Substances 0.000 abstract description 3
- 230000003078 antioxidant effect Effects 0.000 abstract description 3
- 229960003276 erythromycin Drugs 0.000 abstract description 3
- 108010059993 Vancomycin Proteins 0.000 abstract description 2
- 229960003165 vancomycin Drugs 0.000 abstract description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 abstract description 2
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 239000001963 growth medium Substances 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 11
- 239000006041 probiotic Substances 0.000 description 10
- 235000018291 probiotics Nutrition 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 238000007865 diluting Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 6
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 229960004488 linolenic acid Drugs 0.000 description 6
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 238000005502 peroxidation Methods 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000012086 standard solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FPFSGDXIBUDDKZ-UHFFFAOYSA-N 3-decyl-2-hydroxycyclopent-2-en-1-one Chemical compound CCCCCCCCCCC1=C(O)C(=O)CC1 FPFSGDXIBUDDKZ-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000193171 Clostridium butyricum Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- ZLXPLDLEBORRPT-UHFFFAOYSA-M [NH4+].[Fe+].[O-]S([O-])(=O)=O Chemical compound [NH4+].[Fe+].[O-]S([O-])(=O)=O ZLXPLDLEBORRPT-UHFFFAOYSA-M 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- XGGLLRJQCZROSE-UHFFFAOYSA-K ammonium iron(iii) sulfate Chemical compound [NH4+].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O XGGLLRJQCZROSE-UHFFFAOYSA-K 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000010227 cup method (microbiological evaluation) Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000015784 hyperosmotic salinity response Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052603 melanterite Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000004260 plant-type cell wall biogenesis Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- -1 potassium ferricyanide Chemical compound 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/513—Adolescentes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
本发明公开了一种青春双歧杆菌菌株ZJ2,该菌株是从健康百岁长寿老人粪便中分离筛选而得,该菌株对酸和胆盐具有良好的耐受作用,培养原液以及5倍浓缩液对小鼠无毒性作用,青春双歧杆菌ZJ2对外源加入的0.1mg/ml胆固醇孵育48h后胆固醇的降解率29.15%,对大肠杆菌ATCC33849、沙门氏菌ATCC14028、绿脓杆菌ATCC9027、肺炎克雷伯杆菌ATCC700603、金黄色葡萄球菌NCTC8325、单增李斯特菌ATCC19115均有一定的抑制效果以及对菌株ZJ2对万古霉素(Van)、红霉素(Ery)以及四环素(Tet)敏感,同时青春双歧杆菌菌株ZJ2具有良好的抗氧化能力。
Description
技术领域
本发明属于益生菌技术领域,具体涉及一种青春双歧杆菌菌株。
背景技术
肠道作为人体最庞大、最复杂的微生态***,在维持机体正常免疫防御功能中发挥着极其重要的作用,肠道菌群本身及其代谢产物越来越受到科学家们的重视。人体肠道中定植着大量的微生物。肠道微生物与人体健康与疾病之间存在着十分密切的关系。肠道微生物可分为有益菌、中性菌和有害菌3 大类。有益菌,主要以各种双歧杆菌、乳酸杆菌为代表的益生菌群体,是人体健康不可缺少的要素,可以合成各种维生素,发挥着参与食物的消化,促进肠道蠕动,抑制致病菌群的生长,分解有害、有毒物质等重要作用。有害菌,即能够产生致癌物等有害物质,或者影响免疫***的功能的致病菌。中性菌,即具有双重作用的细菌,如大肠杆菌、肠球菌等,在正常情况下对健康有益,一旦肠道内的益生菌屏障受到破坏,肠道通透性增加,中性菌就会加入有害菌的大军,威胁人体健康。
益生菌是一类可以改善人体肠内微生态的平衡,并对机体有正面效益的活性微生物,能够定植于人体肠道、生殖***内,具有缓解不耐乳糖症状、预防生殖***感染、增强人体免疫力、降胆固醇、帮助吸收营养成分、增强植物新陈代谢等有益作用。人体内常见的益生菌主要有嗜酸乳杆菌、双歧杆菌、乳酸菌、酪酸梭菌、酵母菌和放线菌等,其中双歧杆菌是一种专性厌氧的***,不运动,形态多变,呈现弯曲杆状、L、V或Y形等多种形态。细胞呈杆状,其末端分叉,故命名为双歧杆菌。
双歧杆菌主要寄居在人体的胃肠道内,分布在胃肠的数量及种类会随年龄阶段的增长而减少,分布最多的是母乳婴儿时期,是健康者肠道内的优势菌种,其种类和数量随年龄呈动态变化,而且其改变与机体内许多生理病理变化关系密切。随着年龄增加,有害菌的数量增多,产生的毒素加速肠道老化和免疫力下降等因素,正常老年人肠道有益菌(如双歧杆菌)的丰度降低。然而有文章报道发现健康百岁老人肠道内的双歧杆菌种类丰富,研究者对这些百岁老人进行体检发现:他们体内的双歧杆菌等有益菌占比率明显高于普通老人,相当于青少年水平。通过多年考察,研究者们认为这些百岁老人与其所在的良好的自然生态环境和生活习惯密不可分。
发明内容
本发明的目的在于提供一种青春双歧杆菌菌株,克服了现有技术的不足,在长寿老人的粪便中分离筛选出了青春双歧杆菌菌株ZJ2,并对该菌株的环境耐受情况、抑菌作用、自由基的清除能力和还原力大小进行试验。
为解决上述问题,本发明所采取的技术方案如下:
一种青春双歧杆菌菌株,所述菌株由健康百岁长寿老人的粪便中分离筛选得到的,命名为青春双歧杆菌(Bifidobacterium adolescents)ZJ2,且已于 2019年11月04日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏编号为CGMCC NO.18901。
本发明还保护了一种活性成分中含有上述青春双歧杆菌菌株ZJ2的菌剂。
本发明还保护了一种成分中含有上述青春双歧杆菌菌株ZJ2的菌剂的组合物。
本发明还保护了上述组合物或者菌剂在食品中的应用。
本发明还保护了上述组合物或者菌剂在保健产品中的应用。
本发明最后还保护了上述组合物或者菌剂在抑制胃肠道致病菌药物中的应用。
青春双歧杆菌ZJ2菌株在pH 3.0环境中孵育2h后仍能存活,对0.3%胆盐环境也有一定的耐受;对青春双歧杆菌ZJ2对大肠杆菌ATCC33849、沙门氏菌ATCC14028、绿脓杆菌ATCC9027、肺炎克雷伯杆菌ATCC700603、金黄色葡萄球菌NCTC8325、单增李斯特菌ATCC19115均有抑制效果;对外源加入0.1mg/ml胆固醇孵育48h后胆固醇的降解率为29.15%;且对DPPH自由基和ABTS+自由基有良好的清除能力,有良好的还原力并对亚麻酸过氧化有一定抑制作用。
本发明与现有技术相比较,具有以下有益效果:
本发明在长寿老人的粪便中分离筛选出了青春双歧杆菌菌株ZJ2,并对该菌株的环境耐受情况、抑菌作用、自由基的清除能力和还原力大小进行试验;经过试验发现,该菌株对胃肠道内的致病菌具有一定的抑制作用,有助于恢复胃肠道微生物菌群的稳定和协调。
附图说明
图1为青春双歧杆菌ZJ2菌株菌落示意图。
图2为青春双歧杆菌ZJ2菌株与相关种的16S rDNA序列***发育树。
图3为青春双歧杆菌ZJ2菌株对酸的耐受情况的柱状统计图。
图4为青春双歧杆菌ZJ2菌株对胆盐的耐受情况的柱状统计图。
图5为青春双歧杆菌ZJ2菌株对几种病原菌的抑菌作用效果图。
图6为青春双歧杆菌ZJ2菌株对DPPH自由基的清除能力的柱状统计图。
图7为青春双歧杆菌ZJ2菌株的还原力大小的柱状统计图。
图8为青春双歧杆菌ZJ2菌株对亚麻酸过氧化的抑制作用的柱状统计图。
图9为青春双歧杆菌ZJ2菌株对ABTS+自由基的清除能力的柱状统计图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
实施例1分离筛选鉴定
在厌氧工作站里,取安徽省亳州市谯城区的健康百岁长寿老人的粪便样品2g,用无菌生理盐水进行梯度稀释,分别涂布于BL、BBL、BS、TPY及 MRS-L等固体培养基,于37℃厌氧培养24-48h后选取菌落数量适中的平板,挑取乳白色圆形菌落进行划线分离2-3次,得到纯化的单菌落。将分离得到的菌株分别进行液体培养,所得到的菌体用于抽取菌株的基因组DNA,利用设计的引物扩增其基因片段,将扩增的16S rDNA基因片段测序,测序结果经NCBI数据库Blast比对,初步判断菌株的种属分类。
根据《益生菌类保健食品申报与审评规定(试行)》,判定分离筛选出的菌株属于益生菌类保健品的菌株,将筛选纯化后的菌株接种于TPY肉汤中,菌液与50%的甘油(生理盐水配置)等体积混合,保存于-80℃冰箱备用。
⑴定性鉴定
按照《伯杰细菌鉴定手册》和《常见细菌***鉴定手册》,并结合之前观察的菌株形态特征和生理生化特性,对分离得到的ZJ2菌株进行初步鉴定,可初步判断该菌株归属于双歧杆菌。
该菌株为厌氧的***,菌株细胞长而稍弯曲,有多种形态,如Y型、V型、长杆状、弯曲弧状。该菌株菌落光滑、凸圆、边缘完整、乳脂白色、具有柔软的质地,如图1所示。该菌株的生理生化特征如表1所示。
表1 ZJ2菌株API 20鉴定结果
符号说明:“+”,阳性;“-”,阴性。
使用细菌基因组提取试剂盒提取基因组DNA,PCR扩增目标序列后进行测序,将测序结果在数据库中进行序列比对,获得与其相似性较高的其他菌株的基因序列,详见序列表。
使用MEGA 7.0软件构建***发育树,如图2所示,确定该菌的种属分类地位,由进化树图可看出ZJ2菌株定位在青春双岐杆菌。
采用MEGA7.0软件,邻位连接法显示“青春双歧杆菌ZJ2菌株”与相关种的16S rDNA序列***发育树,进行1000次的相似度重复计算,图中发育树节点只显示Bootstrap值大于50%数值,上标的“T”表示模式菌株。
该菌株已于2019年11月04日保藏于中国微生物菌种保藏管理委员会普通微生物中心,保藏单位地址:北京市朝阳区北辰西路1号院3号;保藏编号为CGMCC NO.18901,建议的分类学名称:青春双歧杆菌(Bifidobacterium adolescentis)。
实施例2动物毒性试验
选用北京维通利华实验动物技术有限公司繁殖的SPF级ICR小鼠(许可证编号SCXK(京)2016-0006)80只,雌雄各半,雄性小鼠体重范围16.0-25.0g,雄性小鼠体重范围16.0-25.0g。在北京维通利华实验动物技术有限公司动物房 (许可证编号为SYXK(京)2017-0022)饲养。
将送检的经菌种鉴定后的青春双歧杆菌ZJ2菌株转接到MRS肉汤培养基中,置于36℃,厌氧培养2天后,作为培养物原液备用。取部分培养物原液浓缩5倍,作为培养物5倍浓缩液备用。
取ICR小鼠80只,雌雄各半,分别随机为4组,每组10只。剂量组设置为:培养基空白对照组,培养基5倍浓缩空白对照组,培养物原液组,培养物5倍浓缩组。将受试物以20.0ml/kg BW剂量给小鼠灌胃,连续灌胃3天,观察7天,记录实验过程中小鼠的体重变化,中毒表现及死亡情况。
青春双歧杆菌ZJ2菌株培养物原液经梯度稀释后活菌计数结果(接种量为0.1ml),计数结果为培养物原液中含有青春双歧杆菌ZJ2菌株的数量为4.7×107 CFU/ml。
青春双歧杆菌ZJ2菌株(Bifidobacterium adolescents ZJ2)培养物原液和 5倍浓缩液与各自对照组相比,对小鼠体重增长的影响无显著性差异(p> 0.05),同时未观察到受试小鼠有毒性反应或死亡,结果如表2、表3和表4 所示。
表2青春双歧杆菌ZJ2菌株(Bifidobacterium adolescentsZJ2)培养物
对雌性小鼠体重的影响
(Mean±SD)
结果说明:雌性小鼠的初始体重和终体重在培养物组与其相应对照组间比较均无显著性差异(p>0.05),即在试验期间青春双歧杆菌ZJ2菌株(B ifidobacteriumadolescents ZJ2)培养物对雌性小鼠的体重无影响。
表3青春双歧杆菌ZJ2菌株(Bifidobacterium adolescents ZJ2)培养物
对雄性小鼠体重的影响
(Mean±SD)
结果说明:雄性小鼠的初始体重和终体重在培养物组与其相应对照组间比较均无显著性差异(p>0.05),即在试验期间青春双歧杆菌ZJ2菌株( Bifidobacteriumadolescents ZJ2)培养物对雄性小鼠的体重无影响。
表4青春双歧杆菌ZJ2菌株(Bifidobacterium adolescents ZJ2)培养物
对小鼠的急性毒力作用
结果说明:将青春双歧杆菌ZJ2菌株(Bifidobacterium adolescents ZJ2) 培养物原液和5倍浓缩液,以20.0ml/kg BW的剂量给小鼠连续灌胃3天,观察7天,未观察到受试小鼠有毒性反应或死亡,表明ZJ2菌株对小鼠无急性毒力作用。
实施例3耐受性实验
胃液的pH一般维持在2.5-3.5之间,进食后食物在胃内停留时间为2-3h。胃液有强酸性,可激活胃蛋白酶原,杀死随食物进入胃内的一些细菌,胆盐由肝脏合成储存于胆囊分泌到肠道,通常情况下肠道内的胆盐浓度大约在 0.03%-0.3%范围内。益生菌是对人体健康有着极其重要的作用,能帮助肠道抵御疾病及维持肠道正常功能,因此若想要益生菌正常发挥其生理功能则其必须具备耐受胃液的强酸和消化道的胆盐环境的特性。
实验方法:
1、将筛选出的青春双歧杆菌菌株培养在37℃的厌氧条件下,接种量为 4%,分别取不同pH的培养基培养0h、2h的菌液,稀释适当比例后涂平板培养24h计活菌数。
结果表明:如图3所示,ZJ2菌株可耐受pH 2.0的酸性环境下孵育2h仍可正常存活,耐酸性良好。
2、将筛选出的青春双歧杆菌ZJ2菌株培养在37℃的厌氧条件下,双歧杆菌的接种量为4%,分别取不同浓度胆盐的TPY肉汤,培养0h、3h的菌液稀释适当比例,涂平板培养24h计数。评价双歧杆菌的胆盐耐受性,
结果表明:由图4可看出ZJ2菌株可在0.3%的胆盐环境中仍有一定的存活率。
实施例4抑菌能力实验
实验方法:牛津杯法测定双歧杆菌对大大肠杆菌ATCC33849、沙门氏菌ATCC14028、绿脓杆菌ATCC9027、肺炎克雷伯杆菌ATCC700603、金黄色葡萄球菌NCTC8325、单增李斯特菌ATCC19115的抑制作用。
甘油保存的病源指示菌接种到TSB液体培养基中培养8h,稀释至OD600=1.0,再用生理盐水1:103稀释,吸取稀释的菌悬液200μl涂布于TSB固体培养基进行抑菌实验。牛津杯加入200μl培养后的双歧杆菌菌液以及无细胞上清液,以未接种的培养基作为对照,每组重复三次,37℃培养24h,测量抑菌圈的大小,评价双歧杆菌的抑菌能力。
结果表明:如表5所示,青春双歧杆菌ZJ2对大肠杆菌ATCC33849、沙门氏菌ATCC14028、绿脓杆菌ATCC9027、肺炎克雷伯杆菌ATCC700603、金黄色葡萄球菌NCTC8325、单增李斯特菌ATCC19115均有抑制作用,其中对单增李斯特菌的抑制能力最强,对肺炎克雷伯杆菌抑制能力最弱。
表5青春双歧杆菌ZJ2对几种病原菌的抑制作用
a抑菌圈的值为重复三次的平均值±标准误差。
实施例5抗生素敏感性实验
抗生素通过干扰细胞壁合成(青霉素、万古霉素)、损伤胞膜(氨基糖苷类:链霉素、卡那霉素)、抑制细菌蛋白质合成(四环素类:四环素;大环内酯类:红霉素)和抑制核酸合成(利福平;喹诺酮类:诺氟沙星)等方式发挥抑菌或杀菌作用,通过MIC法检测双歧杆菌对8种抗生素的敏感性。
实验方法:
受试菌液准备:受试菌株按1%接种培养18h,测定其OD600nm值,用 TPY培养基稀释菌液浓度为5.0×105-1.0×106cfu/ml。
抗生素准备:用蒸馏水或无水乙醇配置抗生素的母液,再用TPY肉汤将各抗生素稀释到实验所需最大浓度,再用TPY肉汤倍比稀释8个梯度。
96孔板每孔加75μl不同浓度的抗生素和75μl已准备好的菌液混匀,每个抗生素作3个平行,于37℃厌氧培养24h后观察菌液生长情况。菌液未长的最低浓度记作该抗素的MIC。
结果表明:如表6所示,菌株ZJ2对利万古霉素(Van)、红霉素(Ery) 以及四环素(Tet)敏感。
表6青春双歧杆菌ZJ2对8种抗生素的耐药性
注:EFSA即欧洲食品***,≧标准值判定为“耐受”;<标准判定为“不耐受”。
实施例6抗氧化能力实验
实验方法:
将37℃厌氧培养18h后的菌株培养液经6000r/min离心10min获得双歧杆菌菌体细胞及无细胞上清液备用。收集的菌体用pH 7.4的PBS缓冲液洗涤菌体细胞并重悬,调整其浓度为1×109CFU/ml作为完整的菌体细胞在适当的缓冲液中重悬。PBS快速洗涤菌体两次并进行冰浴超声,然后8000r/min 离心20min,收集上清液即为无细胞提取物,备用。
(1)清除DPPH自由基能力测定
取0.8ml样品中加入1ml 0.2mmol DPPH无水乙醇溶液,室温避光反应 30min,6000r/min离心10min,取上清液在波长517nm处测定吸光度。对照组以等体积蒸馏水代替样品溶液,并以等体积蒸馏水和无水乙醇混合液空白调零。
计算公式:清除率=[1-A517(样品)/A517(对照)]×100%。以0.1mg/ml 的抗坏血酸溶液为阳性对照。
结果表明:如图6所示,完整细胞和无细胞提取物对DPPH的清除效果均超过了60%。
(2)还原力的测定
取0.5ml样品加入0.5ml pH 6.6的PBS缓冲液(0.02M)和0.5ml铁***(1%),混匀后于50℃水浴中保温20min,迅速冷却,加0.5ml三氯乙酸(10%),混匀后3000r/min离心10min。移取1.5ml上清液于试管中,加入0.2ml FeCl3(0.1%),700nm测定吸光度。用PBS作为阴性对照,吸光度值越大表示待测样品的还原能力越强,制作半胱氨酸还原力的标准曲线,用等效半胱氨酸的量表示还原力大小。
结果表明:青春双歧杆菌ZJ2具有良好的还原力,如图7所示,青春双歧杆菌ZJ2还原力大小的范围为69.57-56.83(μM)。
(3)抑制亚麻酸的过氧化作用(TAALA)
1.5%(v/v)亚麻酸(96%的乙醇溶解)用生理盐水1:125v/v稀释,吸取 400ml稀释后的溶液加入15ml 0.01%十二烷基硫酸钠(w/v)和45ml的样品溶液混匀。反应开始通过添加100ml FeSO4·7H2O(0.1g/L),混匀后于37℃反应60min后,加入35ml 0.25%(v/v)丁基羟基甲苯溶液终止反应。然后,加入500ml 0.1mol/L的醋酸缓冲液(pH3.5)和1ml的0.6%(w/v)硫代巴比妥酸(TBA)溶液,80℃加热40min,混合液冷却至室温,加入0.5ml预冷的Hcl(5mol/L)和2ml预冷的正丁醇。3000r/min离心10min测定了534nm处上清液的吸光度。以生理盐水代替样品作为空白对照。TAALA表示为抑制亚麻酸过氧化的百分率(TAALA),定义如下:
抑制率=[1-A534(样品)/A534(对照)]。
结果表明:如图8所示,青春双歧杆菌ZJ2对抑制亚麻酸的过氧化具有良好的作用,其中,完整细胞的抗氧化能力要优于无细胞上清液。
(4)清除ABTS+自由基能力测定
7.4mmol/L ABTS和2.6mM过硫酸钾混合,混合物在黑暗的室温下放置 12-16小时,直到达到稳定的氧化状态(室温保存2d)。PBS缓冲液(pH7.4) 或95%乙醇稀释40~50倍,在734nm吸光度下OD值达到0.7±0.02,备用。 0.2ML工作液与10ml样品混合置于冰上,6min后测OD。抑制率通过Trolox 的浓度表示。
结果表明:如图9所示,ZJ2菌株完整细胞和无细胞提取物的等效Trolox 量分别为359.87±21.17和430.00±9.15(μM)。
实例7胆固醇降解实验
实验方法:
MRS-CHOL(胆固醇MRS培养基):MRS-L培养基(MRS专用培养基 +0.5g/L半胱氨酸)+0.1mg/ml胆固醇,过滤除菌。胆固醇标准液:即胆固醇浓度为1.0mg/ml,100mg胆固醇,用少量无水乙醇溶解并定容至100ml,即胆固醇标准溶液,放置0℃~4℃密封。硫酸铁铵显色剂:4.463g硫酸铁铵溶于100ml 85%磷酸中,即为储备液,再取10ml该储备液用浓硫酸定容至100ml,即为显色剂。
取培养18h后的双歧杆菌,按1%的接种量接种至MRS-CHOL培养基中,等体积未接种的MRS-CHOL培养基作为空白对照,37℃厌氧培养48h,测定双歧杆菌对胆固醇的降解率:取3ml菌液6000r/min离心10min,取上清液2ml 于50ml离心管中,加无水乙醇至10ml,充分混匀,4500r/min离心10min,取上清液1ml至12ml离心管中,缓缓加入2ml硫酸铁铵显色剂(若直接用菌液上清液加显色剂显示颜色很深),立即摇匀,室温下放置30min后测各管的OD560nm值,计算双歧杆菌对胆固醇的降解率。
W=(A-B)/A×100%
注:A:未接种双歧杆菌的MRS-CHOL培养基中胆固醇的含量(即空白对照),mg;B:双歧杆菌在MRS-CHOL培养基中发酵后胆固醇的含量,mg;W: 胆固醇降低率,%。
结果表明:如表7所示,外源加入的0.1mg/ml胆固醇孵育48h后青春双歧杆菌ZJ2的胆固醇降解率为29.15%,表明青春双歧杆菌ZJ2具有良好的降解胆固醇的能力。
表7降解胆固醇能力的测定
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。不应将权利要求中的任何附图标记视为限制所涉及的权利要求。
SEQUENCE LISTING
<110> 卓源健康科技有限公司
<120> 一种青春双歧杆菌菌株及其应用
<130> 2019.10.22
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 1428
<212> DNA
<213> 1
<400> 1
tgcttacaca tgcaagtcga acgggatccc aggagcttgc tcctgggtga gagtggcgaa 60
cgggtgagta atgcgtgacc gacctgcccc atacaccgga atagctcctg gaaacgggtg 120
gtaatgccgg atgctccagt tgaccgcatg gtcctctggg aaagcttttg cggtatggga 180
tggggtcgcg tcctatcagc ttgatggcgg ggtaacggcc caccatggct tcgacgggta 240
gccggcctga gagggcgacc ggccacattg ggactgagat acggcccaga ctcctacggg 300
aggcagcagt ggggaatatt gcacaatggg cgcaagcctg atgcagcgac gccgcgtgcg 360
ggatgacggc cttcgggttg taaaccgctt ttgactggga gcaagccctt cggggtgagt 420
gtacctttcg aataagcacc ggctaactac gtgccagcag ccgcggtaat acgtagggtg 480
caagcgttat ccggaattat tgggcgtaaa gggctcgtag gcggttcgtc gcgtccggtg 540
tgaaagtcca tcgcttaacg gtggatccgc gccgggtacg ggcgggcttg agtgcggtag 600
gggagactgg aattcccggt gtaacggtgg aatgtgtaga tatcgggaag aacaccaatg 660
gcgaaggcag gtctctgggc cgtcactgac gctgaggagc gaaagcgtgg ggagcgaaca 720
ggattagata ccctggtagt ccacgccgta aacggtggat gctggatgtg gggaccattc 780
cacggtctcc gtgtcggagc caacgcgtta agcatcccgc ctggggagta cggccgcaag 840
gctaaaactc aaagaaattg acgggggccc gcacaagcgg cggagcatgc ggattaattc 900
gatgcaacgc gaagaacctt acctgggctt gacatgttcc cgacagccgt agagatacgg 960
tctcccttcg gggcgggttc acaggtggtg catggtcgtc gtcagctcgt gtcgtgagat 1020
gttgggttaa gtcccgcaac gagcgcaacc ctcgccctgt gttgccagca cgtcatggtg 1080
ggaactcacg ggggaccgcc ggggtcaact cggaggaagg tggggatgac gtcagatcat 1140
catgcccctt acgtccaggg cttcacgcat gctacaatgg ccggtacaac gggatgcgac 1200
accgcgaggt ggagcggatc ccttaaaacc ggtctcagtt cggattggag tctgcaaccc 1260
gactccatga aggcggagtc gctagtaatc gcggatcagc aacgccgcgg tgaatgcgtt 1320
cccgggcctt gtacacaccg cccgtcaagt catgaaagtg ggtagcaccc gaagccggtg 1380
gcccaacctt ttggggggag ccgtctaagg gagaccttcc gaggttta 1428
Claims (6)
1.一种青春双歧杆菌菌株,其特征在于:所述菌株由健康百岁长寿老人的粪便中分离筛选得到的,命名为青春双歧杆菌(Bifidobacterium adolescents)ZJ2,且已于2019年11月04日保藏于中国微生物菌种保藏中心,保藏编号为CGMCC NO.18901。
2.一种菌剂,其特征在于:所述菌剂的活性成分中含有权利要求1所述青春双歧杆菌菌株ZJ2。
3.一种组合物,其特征在于:所述组合物的成分中含有权利要求2所述青春双歧杆菌菌株ZJ2的菌剂。
4.一种权利要求3所述的组合物在食品中的应用。
5.一种权利要求3所述的组合物在保健产品中的应用。
6.一种权利要求3所述的组合物在制备抑制胃肠道致病菌药物中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011420948.4A CN112725219B (zh) | 2020-12-08 | 2020-12-08 | 一种青春双歧杆菌菌株及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011420948.4A CN112725219B (zh) | 2020-12-08 | 2020-12-08 | 一种青春双歧杆菌菌株及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112725219A CN112725219A (zh) | 2021-04-30 |
CN112725219B true CN112725219B (zh) | 2022-05-20 |
Family
ID=75598355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011420948.4A Active CN112725219B (zh) | 2020-12-08 | 2020-12-08 | 一种青春双歧杆菌菌株及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112725219B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113249264B (zh) * | 2021-06-03 | 2021-11-23 | 北京量化健康科技有限公司 | 一株青春双歧杆菌及其在代谢综合征中的应用 |
CN115721664A (zh) * | 2021-08-31 | 2023-03-03 | 瑞微(深圳)生物科技有限公司 | 青春双歧杆菌在制备用于治疗炎症相关疾病的药物中的应用 |
CN115216410A (zh) * | 2022-08-15 | 2022-10-21 | 广西大学 | 一种长寿老人源双歧杆菌分离鉴定的方法 |
CN116286535B (zh) * | 2023-03-27 | 2024-01-30 | 湖南绿韵数字化健康科技有限公司 | 一种含益生菌的胶原蛋白肽组合物及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108707565A (zh) * | 2018-06-06 | 2018-10-26 | 北京博锦元生物科技有限公司 | 一种两歧双歧杆菌及其应用 |
CN110368406A (zh) * | 2019-08-20 | 2019-10-25 | 江南大学 | 青春双歧杆菌ccfm1062在制备功能性菌剂、食品和/或药物中的应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3904502A3 (en) * | 2013-02-04 | 2022-02-23 | Seres Therapeutics, Inc. | Compositions and methods |
-
2020
- 2020-12-08 CN CN202011420948.4A patent/CN112725219B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108707565A (zh) * | 2018-06-06 | 2018-10-26 | 北京博锦元生物科技有限公司 | 一种两歧双歧杆菌及其应用 |
CN110368406A (zh) * | 2019-08-20 | 2019-10-25 | 江南大学 | 青春双歧杆菌ccfm1062在制备功能性菌剂、食品和/或药物中的应用 |
Non-Patent Citations (3)
Title |
---|
Competitive inhibition of adherence of enterotoxigenic Escherichia coli, enteropathogenic Escherichia coli and Clostridium difficile to intestinal epithelial cell line Lovo by purified adhesin of Bifidobacterium adolescentis 1027;Shi-Shun Zhong et al.;《World J Gastroenterol》;20040601;第10卷(第11期);第1630-1633页 * |
Complete Genome Sequence of Bifidobacterium adolescentis ZJ2, Isolated from a Centenarian in Anhui, China;Zeyu Jin et al.;《Microbiol Resour Announc》;20200716;第9卷(第29期);第1-3页 * |
长寿老人源双歧杆菌优良菌株的筛选;李平兰等;《微生物学通报》;20051231;第32卷(第3期);第7-12页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112725219A (zh) | 2021-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112725219B (zh) | 一种青春双歧杆菌菌株及其应用 | |
Hossain et al. | Identification and growth characterization of a novel strain of Saccharomyces boulardii isolated from soya paste | |
CN108220206A (zh) | 一种长双歧杆菌及其应用 | |
CN111534446A (zh) | 罗伊氏乳杆菌及其应用 | |
AU2020103929A4 (en) | Bacillus coagulans strain BACO-17 with high germination rate in the intestines and its uses for promoting gastrointestinal health | |
CN110628663B (zh) | 一株鼠李糖乳杆菌及其高密度培养方法和应用 | |
CN110373368B (zh) | 一种长双歧杆菌菌株zj1及其应用 | |
CN111100810B (zh) | 一株植物乳杆菌dnb1及其胞外多糖和应用 | |
CN108018236B (zh) | 一种降低α-葡萄糖苷酶活性的空间植物乳杆菌SS18-37及其应用 | |
CN110577912A (zh) | 一种格氏乳杆菌及其在制备发酵乳中的应用 | |
CN111281895A (zh) | 用于治疗结肠炎的乳酸菌及其应用 | |
CN114874951A (zh) | 一种新型鼠李糖乳杆菌菌株及其应用 | |
Ghatani et al. | Assessment of probiotic characteristics of lactic acid bacteria isolated from fermented yak milk products of Sikkim, India: Chhurpi, Shyow, and Khachu | |
CN103710290A (zh) | 源于广西巴马长寿村的益生菌鼠李糖乳杆菌hsryfm1301及其应用 | |
Rapsang et al. | Molecular and probiotic functional characterization of Lactobacillus spp. associated with traditionally fermented fish, Tungtap of Meghalaya in northeast India | |
CN112538448B (zh) | 一种从雪莲菌中定向筛选的具有益生特性的乳酸菌、筛选方法和应用 | |
Yan et al. | Probiotic potential of Lactiplantibacillus plantarum ZFM4 isolated from pickles and its effects on human intestinal microecology | |
CN117143767A (zh) | 可调节肠道菌群的母乳源发酵粘液乳杆菌msjk0025及其应用 | |
CN113913334B (zh) | 一株粪肠球菌ef-za1107-06及其应用 | |
CN105624071A (zh) | 一株唾液乳杆菌xjp2及其应用 | |
CN108004171B (zh) | 一种降低α-葡萄糖苷酶活性的空间植物乳杆菌SS18-5及其应用 | |
CN113881592B (zh) | 一株罗伊氏乳杆菌及其应用 | |
CN111004735A (zh) | 一株发酵乳杆菌及其在改善肠道健康方面的应用 | |
CN105754886A (zh) | 一株无毒蜡样芽孢杆菌株pBC-1及其应用 | |
CN114806944A (zh) | 植物乳杆菌lp11、其发酵液及制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |